Apolipoprotein A1 -75 G/A and +83 C/T polymorphisms and renal cancer risk. Issue 1 (December 2015)

• Record Type: Journal Article
• Authors: Liu, ZhiHong; Xiao, YingMing; Tang, LiangYou; Jiang, Liang; Wang, YuJie; Zhang, RuoChen; Wei, Qiang; Lu, YiPing
• Is Part Of: Lipids in health and disease. Volume 14:Issue 1(2015)
• Page Start: 1
• Page End: 6
• Publication Date: 2015-12
• Subjects: Apolipoprotein A1 -- Renal cancer -- Gene polymorphism; Lipids -- Periodicals; Lipids in human nutrition -- Periodicals; Lipids -- Metabolism -- Disorders -- Periodicals; 616.3997
• DOI: 10.1186/s12944-015-0132-0
• Languages: English
• ISSNs: 1476-511X

Abstract

Abstract Background Apolipoprotein A1 (ApoA1) is the major apoprotein constituent of high-density lipoprotein that can play important roles in tumor invasion and metastasis. The objective of the present study was to evaluate the association of two genetic variants (−75 G/A and +83 C/T) ofAPOA1 with predisposition to renal cancer. Methods A total of 432 subjects, including 216 pathologically-proven renal cancer cases and 216 age- and gender-matched healthy controls, were recruited into this hospital-based case–control study. Genotyping of theAPOA1 was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) combined with gel electrophoresis, and then confirmed by direct sequencing. Results Patients with renal cancer had a significantly higher frequency ofAPOA1 -75 AA genotype [odds ratio (OR) = 2.10, 95 % confidence interval (CI) = 1.18, 3.75;P = 0.01] andAPOA1 -75 A allele (OR =1.40, 95 % CI = 1.05, 1.87;P = 0.02) than controls. When stratifying by the distant metastasis status, patients with distant metastasis had a significantly higher frequency ofAPOA1 -75 AA genotype genotype (OR =2.20, 95 % CI = 1.04, 4.68;P = 0.04). Conclusion This study is, to our knowledge, the first to examine prospectively an increased risk role ofAPOA1 -75 AA genotype andAPOA1 -75 A allele in renal cancer susceptibility.